Fast and accurate detection of biomarkers at low concentrations in bodily fluids is essential to the fields of diagnostics and drug discovery. In diagnostics, early intervention in many diseases can make a difference in the patient's prognosis; while in drug discovery, biomarkers are used to assess drug efficacy and safety and new biomarkers are identified to better understand biological systems. One problem faced is that biomarkers can be present at concentrations below the limits of detection of commonly used assays. Genisphere's 3DNA dendrimer technology has been previously used to obtain signal amplification in the detection of nucleic acid targets in platforms such as microarrays and Fluorescence in situ Hybridization. Here we summarize our achievements in the application of the 3DNA technology for detection of micro RNAs (miRNA) and proteins (cytokines). miRNAs are increasingly gaining acceptance as biomarkers because they have the ability to repress mRNA expression and have been linked to many types of cancer. Many serum and plasma proteins are also now emerging as predictive biomarkers because in some cases protein expression can be a better indicator of disease onset, and the presence of DNA or RNA is not always indicative of protein expression. We have evaluated the use of the 3DNA dendrimers in ELISAs, protein microarrays, and bead-based assays. For cytokine detection, the adaptation of the dendrimer technology to standard assays resulted in signal amplifications of up to 10-fold. Finally, miRNA detection using the dendrimer technology was also successfully utilized on ELOSA and bead-based assays.